PPT-Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage

Vivek Y Reddy MD 1 Douglas N Gibson MD 2 Saibal Kar 3 William ONeill MD 4 Shephal K Doshi MD 5 Rodney P Horton MD 6 Maurice Buchbinder MD 7 Nicole T Gordon BSEE. The following information about the WATCHMAN implant is important for you to know along with medication recommendations and common questions you may have about your implant UNDERSTANDING YOUR HEART This section will discuss the basic function of th Aquaculture Drug Workshop. Bozeman, Montana. July 31, 2013. Meg Oeller, DVM . FDA Center for Veterinary Medicine. 1. Caveat. Please note that these slides have been altered slightly from those used in the presentation at the aquaculture workshop. This was done largely to facilitate making these slides 508 compliant for posting on our website. The pertinent content has not been changed.. versus Warfarin Therapy for Prevention of Stroke . in Patients with Atrial Fibrillation: A Randomized . Non-Inferiority Trial. David R. Holmes, MD. Vivek Y. Reddy, MD. Zoltan G. Turi, MD. Shephal K. Doshi, MD. T. hrombus . at the device, . leakage . at follow-up, . device . embolisation. , . post. -procedural drug regimen and . impact . of center experience . data . from the prospective 1025 patients . EWOLUTION Registry. Meta-Analysis and Implications . David R. Holmes, Jr., M.D.. Mayo Clinic, Rochester . TCT 2014. Washington, D.C.. September 2014. Presenter Disclosure Information. David R. Holmes, Jr., M.D.. “. Watchman II: PROTECT AF/PREVAIL. Vivek Y. Reddy, MD. Helmsley Trust Professor of Medicine. Director, Cardiac Arrhythmia Service. The Mount Sinai Hospital. vivek.reddy@mountsinai.org. Grant support/Consultant. : Boston Scientific, . Percutaneous. Left Atrial Appendage (LAA) Exclusion. Aaditya Vora, MD. Cardiac Electrophysiologist. Baptist heart specialists. Disclosures. None. > . 33M. people with . AF Worldwide. 1. Many patients are unprotected. A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . Osumi. -. Sutherland. What is OWL?. Web Ontology Language. Can express everything in OBO and more. .. . Certified web standard. Fast reasoning software allows:. automated ontology building; error checking; queries . The Randomized MITHRAS Trial. . Philipp . Lurz. , Matthias . Unterhuber. , Karl-Philipp Rommel, Karl-. Patrik. . Kresoja. , . Tobias . Kister. , Christian Besler, Karl . Fengler. , Marcus Sandri, Ingo . Amir Shaikh, MD; David D McManus, . MD,ScM. Assistant Professor,. Department of Medicine. University of Massachusetts Medical School, Worcester, MA, USA. Disclosures. David D McManus, MD, . ScM. has received research funding from: . CARDIAC INTERVENTIONS TODAY 29 A trial septal defect (ASD) is the second most com - mon congenital cardiac anomaly. In this article, we review the physiology of ASD, as well as the indications and m Seminar Atrial septal defectsTal Geva, Jose D Martins, Rachel M WaldAtrial septal defects are the third most common type of congenital heart disease. Included in this group of pulmonary circulations. JR. GENERAL MEDICINE. Introduction. 6-10% of all cardiac . anomalies. M:F = 1:2 [ sinus . venosus. defects 1:1. ]. 1 in 1500 live . births. Most . common congenital abnormality in adult > 40yrs [30-40.